RMTI Stock Analysis: Buy, Sell, or Hold?
RMTI - Rockwell Medical, Inc. (DE) Common Stock
$0.89
0.04 (5.06%)
▲
5d:
-13.28%
30d:
-0.81%
90d:
+10.42%
WAIT
LOW Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
RMTI is down 12.6% this week, but smart money is accumulating calls. Top strike: $1.5 2026-05-15 with 241 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When RMTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RMTI is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RMTI is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RMTI is currently trading at $0.89, which is considered slightly low relative to its 30-day fair value range of $0.89 to $1.02.
Technical Outlook: Technically, RMTI is in a uptrend. Immediate support is located at $0.83, while resistance sits at $1.09. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: RMTI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+235.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RMTI is in a uptrend. Immediate support is located at $0.83, while resistance sits at $1.09. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: RMTI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+235.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$0.89 -
$1.02
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 235.9% below Wall St target ($3.00)
- WARNING: Recommendation downgraded due to -13.3% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$0.89 -
$1.02
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.83
Resistance Level
$1.09
Current Trend
Uptrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-89.32
Wall Street Target
$3.00
(+235.9%)
Revenue Growth (YoY)
-25.6%
Profit Margin
-7.7%
Share & Embed Analysis
Last updated: March 31, 2026 9:58 PM ET
Data refreshes hourly during market hours. Next update: 10:58 PM
Data refreshes hourly during market hours. Next update: 10:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RMTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
John G Cooper
SELL
5079 shares
2025-11-18
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 64 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 57 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 65 BUY |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
